Literature DB >> 2644805

Histologic localization of terminal complement complexes in renal diseases. An immunohistochemical study.

T Ootaka1, M Suzuki, K Sudo, H Sato, J Seino, T Saito, K Yoshinaga.   

Abstract

Histologic localizations of terminal complement complexes (TCCs) were examined and compared with clinical findings in 154 patients with various renal diseases. Immunohistochemical demonstration of TCCs was carried out on ethanol-fixed paraffin-embedded renal biopsy specimens by indirect immunoperoxidase technique. In glomerular diseases that are thought to be immune-complex glomerulonephritis (IC-GN), such as IgA-nephropathy, membranous nephropathy, and systemic lupus erythematosus (SLE), TCCs were demonstrated in a pattern similar to that of immunoglobulins and C3, indicating that TCCs were induced by immune complexes. The intensity of TCC deposition was correlated with the morphologic destruction of glomeruli or serum creatinine levels in IgA-nephropathy, with urine protein in membranous nephropathy, and with serum C4 in SLE. TCC deposits without IC were also observed in tissue damages without disease specificity such as glomerular or vascular sclerosis and tubulointerstitial lesions. These findings suggested the existence of various roles of TCCs in renal injury, according to IC-mediated or non-IC-mediated mechanism acting in individual diseases.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2644805     DOI: 10.1093/ajcp/91.2.144

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  9 in total

1.  Significance of the duration of nephropathy for achieving clinical remission in patients with IgA nephropathy treated by tonsillectomy and steroid pulse therapy.

Authors:  Norio Ieiri; Osamu Hotta; Toshinobu Sato; Yoshio Taguma
Journal:  Clin Exp Nephrol       Date:  2011-09-13       Impact factor: 2.801

2.  C5b-9 does not mediate tubulointerstitial injury in experimental acute glomerular disease characterized by selective proteinuria.

Authors:  Gopala K Rangan
Journal:  World J Nephrol       Date:  2016-05-06

3.  The complement-inhibiting protein, protectin (CD59 antigen), is present and functionally active on glomerular epithelial cells.

Authors:  I A Rooney; A Davies; D Griffiths; J D Williams; M Davies; S Meri; P J Lachmann; B P Morgan
Journal:  Clin Exp Immunol       Date:  1991-02       Impact factor: 4.330

4.  Human carcinomas variably express the complement inhibitory proteins CD46 (membrane cofactor protein), CD55 (decay-accelerating factor), and CD59 (protectin).

Authors:  G A Niehans; D L Cherwitz; N A Staley; D J Knapp; A P Dalmasso
Journal:  Am J Pathol       Date:  1996-07       Impact factor: 4.307

5.  Structure of the VH and VL segments of monoreactive and polyreactive IgA autoantibodies to DNA in patients with systemic lupus erythematosus.

Authors:  M T Kasaian; H Ikematsu; J E Balow; P Casali
Journal:  J Immunol       Date:  1994-03-15       Impact factor: 5.422

6.  Participation of CR1 (CD35), CR3 (CD11b/CD18) and CR4 (CD11c/CD18) in membranoproliferative glomerulonephritis type I.

Authors:  J Soma; T Saito; J Seino; H Sato; T Ootaka; A Yusa; K Abe
Journal:  Clin Exp Immunol       Date:  1995-05       Impact factor: 4.330

Review 7.  Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.

Authors:  Jacob J E Koopman; Mieke F van Essen; Helmut G Rennke; Aiko P J de Vries; Cees van Kooten
Journal:  Front Immunol       Date:  2021-02-11       Impact factor: 7.561

8.  Membrane attack complex (MAC) deposition in renal tubules is associated with interstitial fibrosis and tubular atrophy: a pilot study.

Authors:  Anna Broder; H Michael Belmont; Shudan Wang; Ming Wu; Luis Chiriboga; Briana Zeck; Beatrice Goilav; Shuwei Wang; Alejandra Londono Jimenez; Chaim Putterman; Daniel Schwartz; James Pullman
Journal:  Lupus Sci Med       Date:  2022-01

Review 9.  The Contribution of Complement to the Pathogenesis of IgA Nephropathy: Are Complement-Targeted Therapies Moving from Rare Disorders to More Common Diseases?

Authors:  Felix Poppelaars; Bernardo Faria; Wilhelm Schwaeble; Mohamed R Daha
Journal:  J Clin Med       Date:  2021-10-14       Impact factor: 4.241

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.